Sumitomo Pharma (Suzhou)
Executive Summary
Sumitomo Pharma (Suzhou) is the Chinese subsidiary of Japanese pharmaceutical giant Sumitomo Pharma, leveraging the parent company's global R&D capabilities and market access for the Chinese market. The company benefits from clear BIOSECURE status due to its Japanese parentage, making it an attractive partner for US pharma companies seeking China exposure without regulatory risk. Limited public information suggests a focus on localized development and commercialization of Sumitomo's global portfolio, though specific pipeline details are not readily available.
Structure: As a wholly-owned subsidiary of Japan's Sumitomo Pharma, this entity likely operates as a standard WOFE (Wholly Owned Foreign Enterprise) structure in China, avoiding complex VIE arrangements. The straightforward ownership structure through a Japanese parent simplifies due diligence and reduces regulatory complexity for US partnerships.
BIOSECURE Risk
Japanese parent company ownership provides clear separation from Chinese state control and BIOSECURE Act concerns
Key Exposures:
- •Potential supply chain dependencies on Chinese manufacturers
- •Local regulatory environment exposure
Mitigation: No specific mitigation needed due to Japanese parent ownership structure
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity identified in available data
Approach: Approach through Sumitomo Pharma global BD channels rather than direct subsidiary engagement; focus on China market access opportunities
Red Flags
- ⚠Limited public transparency on operations and pipeline
- ⚠Lack of visible senior management team
- ⚠Unclear commercial strategy and capabilities
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.